These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 21041920

  • 21. Long-term safety, effectiveness and quality of a generic fixed-dose combination of nevirapine, stavudine and lamivudine.
    Laurent C, Kouanfack C, Koulla-Shiro S, Njoume M, Nkene YM, Ciaffi L, Brulet C, Peytavin G, Vergne L, Calmy A, Mpoudi-Ngolé E, Delaporte E.
    AIDS; 2007 Mar 30; 21(6):768-71. PubMed ID: 17413701
    [Abstract] [Full Text] [Related]

  • 22. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
    McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, Lonergan JT, Fisher RL, Williams VC, Hernandez JE, Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL; ESS40010) Study Team.
    Clin Infect Dis; 2004 Jan 15; 38(2):263-70. PubMed ID: 14699460
    [Abstract] [Full Text] [Related]

  • 23. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct 15; 13(73):180-2. PubMed ID: 15499699
    [Abstract] [Full Text] [Related]

  • 24. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
    Saghayam S, Kumarasamy N, Cecelia AJ, Solomon S, Mayer K, Wanke C.
    Clin Infect Dis; 2007 Jan 15; 44(2):295-300. PubMed ID: 17173234
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
    Gulick RM, Smeaton LM, D'Aquila RT, Eron JJ, Currier JS, Gerber JG, Acosta E, Sommadossi JP, Tung R, Snyder S, Kuritzkes DR, Murphy RL, AIDS Clinical Trials Group 373 Study Team.
    J Infect Dis; 2001 Mar 01; 183(5):715-21. PubMed ID: 11181147
    [Abstract] [Full Text] [Related]

  • 27. Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
    Manosuthi W, Kiertiburanakul S, Chaovavanich A, Sungkanuparph S.
    J Med Assoc Thai; 2007 Feb 01; 90(2):244-50. PubMed ID: 17375627
    [Abstract] [Full Text] [Related]

  • 28. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
    Li T, Guo F, Li Y, Zhang C, Han Y, Lye W, He Y, Lu H, Xie J, Huang A, Li Y, Tang X, Wang H, Zhang T, Gao G, Lei J, Zhang X, Wu X, Sun Y, Bai J, Luo L, Wang H.
    Chin Med J (Engl); 2014 Feb 01; 127(1):59-65. PubMed ID: 24384425
    [Abstract] [Full Text] [Related]

  • 29. A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe.
    Zijenah LS, Kadzirange G, Rusakaniko S, Kufa T, Gonah N, Tobaiwa O, Gwanzura C, Matsikire E, Katzenstein DA.
    Cent Afr J Med; 2006 Feb 01; 52(1-2):1-8. PubMed ID: 17892232
    [Abstract] [Full Text] [Related]

  • 30. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Feb 01; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 31. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.
    Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP, Yeni P.
    AIDS; 2002 Dec 06; 16(18):2447-54. PubMed ID: 12461419
    [Abstract] [Full Text] [Related]

  • 32. Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon.
    Dimala CA, Bechem NN, Aroke D, Kadia BM.
    BMC Res Notes; 2017 Nov 28; 10(1):623. PubMed ID: 29183354
    [Abstract] [Full Text] [Related]

  • 33. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
    Bocket L, Yazdanpanah Y, Ajana F, Gerard Y, Viget N, Goffard A, Alcaraz I, Wattré P, Mouton Y.
    J Antimicrob Chemother; 2004 Jan 28; 53(1):89-94. PubMed ID: 14645320
    [Abstract] [Full Text] [Related]

  • 34. Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.
    Saeng-aroon S, Tsuchiya N, Auwanit W, Ayuthaya PI, Pathipvanich P, Sawanpanyalert P, Rojanawiwat A, Kannagi M, Ariyoshi K, Sugiura W.
    Antiviral Res; 2010 Jul 28; 87(1):22-9. PubMed ID: 20382184
    [Abstract] [Full Text] [Related]

  • 35. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA.
    N Engl J Med; 1997 Sep 11; 337(11):725-33. PubMed ID: 9287227
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients.
    Milinkovic A, Martinez E, López S, de Lazzari E, Miró O, Vidal S, Blanco JL, Garrabou G, Laguno M, Arnaiz JA, Leon A, Larrousse M, Lonca M, Mallolas J, Gatell JM.
    Antivir Ther; 2007 Sep 11; 12(3):407-15. PubMed ID: 17591031
    [Abstract] [Full Text] [Related]

  • 38. Prevalence of lipodystrophy and dyslipidemia among patients with HIV infection on generic ART in rural South India.
    Kalyanasundaram AP, Jacob SM, Hemalatha R, Sivakumar MR.
    J Int Assoc Physicians AIDS Care (Chic); 2012 Sep 11; 11(5):329-34. PubMed ID: 21508297
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Sep 11; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 40. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R, Asmuth DM, Grady JJ, McKinsey DS, Green S, Andron L, Pollard RB.
    Int J STD AIDS; 2003 May 11; 14(5):350-5. PubMed ID: 12803944
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.